View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
J Am Acad Dermatol. 2025;92(4):816-824 doi: 10.1016/j.jaad.2024.12.018
The efficacy and safety of tildrakizumab for the treatment of scalp psoriasis are maintained for up to 52 weeks of treatment in a clinical trial setting.
Clin Exp Dermatol. 2025 Apr 24;50(5):952-959 doi: 10.1093/ced/llae530. PMID: 39657275.
Real-world effectiveness and safety data suggest that deucravacitinib is a valuable long-term treatment option for PsO.
RMD Open. 2025;11:e005033. doi: 10.1136/rmdopen-2024-005033.
Mariette et al. investigated the long-term safety of filgotinib with regard to MACE, VTE and malignancy across RA and UC clinical trial populations. Rates of these events remained low overall, with some increases observed in patients aged 65 years and older.
Arthritis Rheumatol. 2025 doi: 10.1002/art.43184 Epub ahead of print
Phase 2 study data show that zimlovisertib + tofacitinib was more effective than tofacitinib alone, in patients with moderate-to-severe RA and an inadequate response to MTX.
J Crohns Colitis. 2025;19(4):jjaf025 doi: 10.1093/ecco-jcc/jjaf025
Reinisch W, et al. report that the efficacy of RZB induction therapy is independent of CS use, with high rates of CS-free outcomes observed in the overall population and among patients with baseline CS use.
Int J Rheum Dis. 2025;28:e70212. doi: 10.1111/1756-185X.70212.
Kaya et al. reported that switching to secukinumab or cycling to another TNFi after first TNFi failure in axSpA led to comparable drug survival, with predictive factors differing by treatment. The study reports that smoking and Achilles enthesitis were associated with higher SEC discontinuation, while high CRP and primary TNFi failure predicted TNFi discontinuation.
Lancet Rheumatol. 2025;7:e274–89 doi: 10.1016/S2665-9913(24)00340-0
Nagy et al. propose a unifying and holistic framework for understanding and addressing the concept of difficult-to-treat (D2T) disease across rheumatology, integrating cross-disciplinary evidence and recommending its incorporation into future disease management strategies. The D2T state requires a comprehensive, holistic, multidisciplinary approach that considers the specific characteristics of each disease and the personalised needs of the patient.
Drug Safety. 2025. Epub ahead of print. doi: 10.1007/s40264-025-01535-
Di Napoli et al. conducted a global pharmacovigilance analysis comparing MACE between JAKis and anti-TNFα therapies in patients with RA. JAKis were more frequently associated with reported MACE, particularly stroke, and had a shorter median time to onset than
anti-TNFα therapy.
Br J Dermatol 2025;192:618–628 doi: 10.1093/bjd/ljae502
Prajapati et al. conducted the PROTOSTAR trial to assess guselkumab in paediatric patients with moderate-to-severe plaque psoriasis. Guselkumab significantly improved skin clearance versus placebo at Wk16, with high response rates sustained through Wk52 and a favourable safety profile.
Rheumatology (Oxford). 2025;64:1131–1137. doi: 10.1093/rheumatology/keae257
Floris et al. conducted a monocentric cohort study to assess the impact of biologic treatment on the development of PsA in patients with PsO. Treatment with biologics significantly reduced the likelihood of PsA development, with lower prevalence observed across different biologic classes and patterns of joint involvement.
